Pitfalls in the measurement and interpretation of thyroid function tests☆

Thyroid function tests (TFTs) are amongst the most commonly requested laboratory investigations in both primary and secondary care. Fortunately, most TFTs are straightforward to interpret and confirm the clinical impression of euthyroidism, hypothyroidism or hyperthyroidism. However, in an important subgroup of patients the results of TFTs can seem confusing, either by virtue of being discordant with the clinical picture or because they appear incongruent with each other [e.g. raised thyroid hormones (TH), but with non-suppressed thyrotropin (TSH); raised TSH, but with normal TH]. In such cases, it is important first to revisit the clinical context, and to consider potential confounding factors, including alterations in normal physiology (e.g. pregnancy), intercurrent (non-thyroidal) illness, and medication usage (e.g. thyroxine, amiodarone, heparin). Once these have been excluded, laboratory artefacts in commonly used TSH or TH immunoassays should be screened for, thus avoiding unnecessary further investigation and/or treatment in cases where there is assay interference. In the remainder, consideration should be given to screening for rare genetic and acquired disorders of the hypothalamic–pituitary–thyroid (HPT) axis [e.g. resistance to thyroid hormone (RTH), thyrotropinoma (TSHoma)]. Here, we discuss the main pitfalls in the measurement and interpretation of TFTs, and propose a structured algorithm for the investigation and management of patients with anomalous/discordant TFTs.

[1]  S. Atkin,et al.  Autoimmune Hypothyroidism Coexisting with a Pituitary Adenoma Secreting Thyroid-Stimulating Hormone, Prolactin and α-Subunit , 2001, Annals of clinical biochemistry.

[2]  R. Fletterick,et al.  Incidental identification of a thyroid hormone receptor beta (THRB) gene variant in a family with autoimmune thyroid disease. , 2013, Thyroid : official journal of the American Thyroid Association.

[3]  J. Hershman,et al.  Conditions and drugs interfering with thyroxine absorption. , 2009, Best practice & research. Clinical endocrinology & metabolism.

[4]  B. Biondi The normal TSH reference range: what has changed in the last decade? , 2013, The Journal of clinical endocrinology and metabolism.

[5]  Michael J Murphy,et al.  Age- and gender-specific TSH reference intervals in people with no obvious thyroid disease in Tayside, Scotland: the Thyroid Epidemiology, Audit, and Research Study (TEARS). , 2013, The Journal of clinical endocrinology and metabolism.

[6]  A. Hollenberg,et al.  The in vivo role of nuclear receptor corepressors in thyroid hormone action. , 2013, Biochimica et biophysica acta.

[7]  A. Uitterlinden,et al.  Association between mutations in a thyroid hormone transporter and severe X-linked psychomotor retardation , 2004, The Lancet.

[8]  A. Farwell Thyroid hormone therapy is not indicated in the majority of patients with the sick euthyroid syndrome. , 2008, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[9]  Donald L St Germain,et al.  Minireview: Defining the roles of the iodothyronine deiodinases: current concepts and challenges. , 2009, Endocrinology.

[10]  J. Morris How do you approach the problem of TSH elevation in a patient on high‐dose thyroid hormone replacement? , 2009, Clinical endocrinology.

[11]  F. Latrofa,et al.  Causes and laboratory investigations of thyrotoxicosis , 2011 .

[12]  P. Chanson,et al.  The changing spectrum of TSH-secreting pituitary adenomas: diagnosis and management in 43 patients. , 2003, European journal of endocrinology.

[13]  K. Brockmann,et al.  A novel syndrome combining thyroid and neurological abnormalities is associated with mutations in a monocarboxylate transporter gene. , 2004, American journal of human genetics.

[14]  L. Thienpont,et al.  IFCC international conventional reference procedure for the measurement of free thyroxine in serum , 2011, Clinical chemistry and laboratory medicine.

[15]  T. van der Poll,et al.  Tumor necrosis factor: a putative mediator of the sick euthyroid syndrome in man. , 1990, The Journal of clinical endocrinology and metabolism.

[16]  E. Anckaert,et al.  FT4 immunoassays may display a pattern during pregnancy similar to the equilibrium dialysis ID-LC/tandem MS candidate reference measurement procedure in spite of susceptibility towards binding protein alterations. , 2010, Clinica chimica acta; international journal of clinical chemistry.

[17]  M. Gurnell,et al.  Reversible pituitary enlargement in the syndrome of resistance to thyroid hormone. , 1998, Thyroid : official journal of the American Thyroid Association.

[18]  M. Inada,et al.  [Thyroid hormone metabolism]. , 1993, Nihon Naibunpi Gakkai zasshi.

[19]  P. Dahlqvist,et al.  National incidence and prevalence of TSH-secreting pituitary adenomas in Sweden. , 2012, The Journal of clinical endocrinology and metabolism.

[20]  F. B. Davis,et al.  Nongenomic actions of thyroid hormone on the heart. , 2002, Thyroid : official journal of the American Thyroid Association.

[21]  J. N. Walker,et al.  A thyroxine absorption test followed by weekly thyroxine administration: a method to assess non-adherence to treatment. , 2013, European journal of endocrinology.

[22]  K. Cusi,et al.  Thyroid function testing in psychiatric illness: Usefulness and limitations , 1997, Trends in Endocrinology & Metabolism.

[23]  G. Steiner,et al.  Influence of heparin on serum free thyroxine. , 1969, The Journal of clinical endocrinology and metabolism.

[24]  R. Weiss,et al.  Autoimmunity in patients with resistance to thyroid hormone. , 2010, The Journal of clinical endocrinology and metabolism.

[25]  S. Kunitake,et al.  Mechanism of the heparin-induced increase in the concentration of free thyroxine in plasma. , 1987, The Journal of clinical endocrinology and metabolism.

[26]  I. Young,et al.  Misleading serum free thyroxine results during low molecular weight heparin treatment. , 1998, Clinical chemistry.

[27]  J. Jaume,et al.  Extremely low doses of heparin release lipase activity into the plasma and can thereby cause artifactual elevations in the serum-free thyroxine concentration as measured by equilibrium dialysis. , 1996, Thyroid : official journal of the American Thyroid Association.

[28]  T. Visser,et al.  Minireview: thyroid hormone transporters: the knowns and the unknowns. , 2010, Molecular endocrinology.

[29]  E. Fliers,et al.  Decreased hypothalamic thyrotropin-releasing hormone gene expression in patients with nonthyroidal illness. , 1997, The Journal of clinical endocrinology and metabolism.

[30]  P. Rae,et al.  The Clinical Utility of a Non-Isotopic Two-Step Assay (DELFIA) and an Analogue Radioimmunoassay (SimulTRAC) for Free Thyroxine Compared , 1991, Annals of clinical biochemistry.

[31]  B. Arafah,et al.  Sex steroids and the thyroid. , 2009, Best practice & research. Clinical endocrinology & metabolism.

[32]  B. Haugen Drugs that suppress TSH or cause central hypothyroidism. , 2009, Best practice & research. Clinical endocrinology & metabolism.

[33]  G. Umpierrez,et al.  Best Practice & Research Clinical Endocrinology & Metabolism , 2011 .

[34]  J E Midgley,et al.  Direct and indirect free thyroxine assay methods: theory and practice. , 2001, Clinical chemistry.

[35]  P. Beck‐Peccoz,et al.  Different responses to chronic somatostatin analogues in patients with central hyperthyroidism , 2005, Clinical endocrinology.

[36]  K. Downes,et al.  A mutation in the thyroid hormone receptor alpha gene. , 2012, The New England journal of medicine.

[37]  T. Nagaya,et al.  Thyroid Hormone Resistance Syndrome , 1991 .

[38]  Soo-Mi Park,et al.  An adult female with resistance to thyroid hormone mediated by defective thyroid hormone receptor α. , 2013, The Journal of clinical endocrinology and metabolism.

[39]  L. D. De Groot Dangerous dogmas in medicine: the nonthyroidal illness syndrome. , 1999, The Journal of clinical endocrinology and metabolism.

[40]  A. Bianco,et al.  Deiodinases: implications of the local control of thyroid hormone action. , 2006, The Journal of clinical investigation.

[41]  J. Stockigt,et al.  EFFECT OF ORAL FRUSEMIDE ON DIAGNOSTIC INDICES OF THYROID FUNCTION , 1987, Clinical endocrinology.

[42]  P. Laurberg,et al.  Narrow individual variations in serum T(4) and T(3) in normal subjects: a clue to the understanding of subclinical thyroid disease. , 2002, The Journal of clinical endocrinology and metabolism.

[43]  A. Leung Thyroid function in pregnancy. , 2012, Journal of trace elements in medicine and biology : organ of the Society for Minerals and Trace Elements.

[44]  H. Ramos,et al.  [Thyroid hormone resistance syndrome]. , 2004, Arquivos brasileiros de endocrinologia e metabologia.

[45]  J. Stockigt,et al.  Medications that distort in vitro tests of thyroid function, with particular reference to estimates of serum free thyroxine. , 2009, Best practice & research. Clinical endocrinology & metabolism.

[46]  M. Gurnell,et al.  What should be done when thyroid function tests do not make sense? , 2011, Clinical endocrinology.

[47]  O. Soldin,et al.  Assessing Thyroid Function in Pregnancy , 2010 .

[48]  V. Darras,et al.  Impact of monocarboxylate transporter-8 deficiency on the hypothalamus-pituitary-thyroid axis in mice. , 2010, Endocrinology.

[49]  L. Schomburg,et al.  Mutations in SECISBP2 result in abnormal thyroid hormone metabolism , 2005, Nature Genetics.

[50]  P. Hamblin,et al.  Relationship between thyrotropin and thyroxine changes during recovery from severe hypothyroxinemia of critical illness. , 1986, The Journal of clinical endocrinology and metabolism.

[51]  F. Brucker-Davis,et al.  Thyrotropin-secreting pituitary tumors. , 1996, Endocrinology and metabolism clinics of North America.

[52]  R. Weiss,et al.  Resistance to Thyroid Hormone , 2004, Reviews in Endocrine and Metabolic Disorders.

[53]  E. Fliers,et al.  Impaired bacterial clearance in type 3 deiodinase-deficient mice infected with Streptococcus pneumoniae. , 2009, Endocrinology.

[54]  G. Barbesino,et al.  Drugs affecting thyroid function. , 2010, Thyroid : official journal of the American Thyroid Association.

[55]  C. Mendel,et al.  Effect of free fatty acids on the concentration of free thyroxine in human serum: the role of albumin. , 1986, The Journal of clinical endocrinology and metabolism.

[56]  L. Degroot,et al.  Megatrials for Clinical Decision Making , 1996, Annals of Internal Medicine.

[57]  E. Krenning,et al.  The sick euthyroid syndrome: changes in thyroid hormone serum parameters and hormone metabolism , 1993, Clinical endocrinology.

[58]  G. Klee Harmonization and standardization of thyroid function tests. , 2010, Clinical chemistry.

[59]  G. Brent,et al.  Maternal thyroid function: interpretation of thyroid function tests in pregnancy. , 1997, Clinical obstetrics and gynecology.

[60]  K. Burman,et al.  Alterations in thyroid function in patients with systemic illness: the "euthyroid sick syndrome". , 1982, Endocrine reviews.

[61]  L. J. Groot,et al.  Dangerous Dogmas in Medicine: The Nonthyroidal Illness Syndrome , 1999 .

[62]  J. Michl,et al.  A characteristic serpin cleavage product of thyroxine-binding globulin appears in sepsis sera. , 2000, The Journal of clinical endocrinology and metabolism.

[63]  J. Lado-Abeal,et al.  Thyroid hormone receptors are down-regulated in skeletal muscle of patients with non-thyroidal illness syndrome secondary to non-septic shock. , 2010, European journal of endocrinology.

[64]  F. Muntoni,et al.  Mutations in the selenocysteine insertion sequence-binding protein 2 gene lead to a multisystem selenoprotein deficiency disorder in humans. , 2010, The Journal of clinical investigation.

[65]  P. Beck‐Peccoz,et al.  Pituitary tumours: TSH-secreting adenomas. , 2009, Best practice & research. Clinical endocrinology & metabolism.

[66]  T. Visser,et al.  Clinical phenotype of a new type of thyroid hormone resistance caused by a mutation of the TRα1 receptor: consequences of LT4 treatment. , 2013, The Journal of clinical endocrinology and metabolism.

[67]  G. Beckett,et al.  Mechanisms behind the non-thyroidal illness syndrome: an update. , 2010, The Journal of endocrinology.

[68]  Stephen Fenlon,et al.  The anaesthetist and the Medicines and Healthcare products Regulatory Agency , 2012 .